Eliem Therapeutics Cash on Hand 2021-2024 | CLYM
Eliem Therapeutics cash on hand from 2021 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Eliem Therapeutics Annual Cash on Hand
(Millions of US $) |
| 2023 |
$107 |
| 2022 |
$124 |
| 2021 |
$136 |
| 2020 |
$20 |
Eliem Therapeutics Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$223 |
| 2024-03-31 |
$105 |
| 2023-12-31 |
$107 |
| 2023-09-30 |
$107 |
| 2023-06-30 |
$103 |
| 2023-03-31 |
$109 |
| 2022-12-31 |
$124 |
| 2022-09-30 |
$123 |
| 2022-06-30 |
$123 |
| 2022-03-31 |
$124 |
| 2021-12-31 |
$136 |
| 2021-09-30 |
$146 |
| 2021-06-30 |
$99 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
